BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, May 13, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 30, 2021
View Archived Issues
Enrollment starts in phase II study of teverelix trifluoroacetate in prostate cancer
Read More
Stragen beings enrollment in phase II trial of STR-324 for postoperative pain
Read More
FDA and China NMPA clear INDs for JMT-601 in NHL
Read More
Phase IIb study of XF-73 nasal gel meets primary efficacy endpoint
Read More
Lenzilumab improves survival without need for IMV in hospitalized patients with COVID-19
Read More
Phase II trial of IONIS-PKK-LRx as treatment for HAE meets endpoints
Read More
Jiangsu Chia Tai Tianqing Pharmaceutical Group, Boision present antibodies binding TSLP
Read More
Adagene reports interim data from ongoing phase I study of ADG-116
Read More
Inflazome divulges new NLRP3 inflammasome inhibitors
Read More
New platinum IV complexes synthesized at VUAB Pharma
Read More
Intra-Cellular Therapies identifies new phosphodiesterase PDE1 inhibitors
Read More
Mission Therapeutics discovers USP30 inhibitors
Read More
First subject dosed in phase I study of Gritstone's second-generation COVID-19 vaccine
Read More
Arenobufagin derivative ZM-226 has antitumor activity with low cardiotoxicity
Read More
IFI27L2A is elevated in microglial cells after stroke
Read More
Daiichi Sankyo compound inhibits G9a/GLP to induce fetal hemoglobin production
Read More
MTD of seliciclib defined at 400 mg for rheumatoid arthritis refractory to TNF blockade
Read More
European Commission approves Pemazyre for cholangiocarcinoma with FGFR2 fusion or rearrangement
Read More
Conditional E.U. marketing authorization for Nexpovio in relapsed or refractory multiple myeloma
Read More
Amryt reports data from study of lomitapide in familial chylomicronemia syndrome
Read More
European Commission approves Evrysdi for spinal muscular atrophy
Read More
Phase III trial of Xospata in relapsed or refractory AML with FLT3 mutation meets OS endpoint
Read More
Gut microbial metabolites facilitate anticancer therapy
Read More
E.U. approval granted to Kesimpta for relapsing MS
Read More
Vazkepa approved in E.U. to reduce cardiovascular risk in adults with elevated triglycerides
Read More